The Global Mammalian Cell Fermentation Technology Market Size is is predicted to exhibit at a 5% CAGR during the forecast period for 2024-2031.
Mammalian cell fermentation is a crucial component of the production of biopharmaceuticals because it is frequently utilized to produce a range of biosimilars, enzymes, vaccines, and other biologics. The procedure uses mammalian cells grown in-vitro with cell culture media which are then treated for fermentation in a bioreactor. The cells use a number of metabolic pathways during this process to create the required byproducts.
With the aid of mammalian cell fermentation technology, novel therapies are being developed due to the biopharmaceutical industry's high levels of research and development (R&D) spending and numerous funding options. The market for mammalian cell fermentation technology is anticipated to develop quickly throughout the projected period due to the expanding demand for innovative and secure treatments across many geographies.
Significant demand for mammalian culture bioprocessing technology is also projected in the market because of these regions' rapid economic development and rising healthcare expenditures.
Furthermore, strategic actions done by important market participants are likely to increase the industry's potential for generating money. For instance, a California-based CDMO called Culture Biosciences piloted its mammalian cell fermentation services in 2020 to take advantage of the expanding market opportunity. Such actions are anticipated to increase the market's growth prospects shortly.
Competitive Landscape:
Some of the mammalian cell fermentation technology market players are:
- Thermo Fisher Scientific, Inc.
- Merck KGaA
- Danaher
- Lonza
- Hoffmann-La Roche Ltd
- Sartorius AG
- AstraZeneca
- Bristol-Myers Squibb
- Amgen
- Gilead Sciences
- Moderna, Inc.
- Regeneron Pharmaceuticals
Market Segmentation:
The mammalian cell fermentation technology market is segmented on the basis of type, application and end-use. Based on type, the market is segregated as Chinese Hamster Ovary (CHO) Cell Fermentation, Human Embryonic Kidney (HEK) Cell Fermentation, Baby Hamster Kidney (BHK) Cell Fermentation, Murine Myeloma Cell Fermentation, Medical Research Council Cell Strain - 5 (MRC-5) Fermentation and Others. By application, the market is segmented into Monoclonal Antibodies, Recombinant Proteins, Biosimilars, Vaccines, Enzymes and Others. By end-use, the market is segmented into Biopharmaceutical Companies, CMOs & CDMOs and Academic and Research Institutes.
Based On Application, The Biosimilars Segment Is Accounted As A Major Contributor In The Mammalian Cell Fermentation Technology Market
The biosimilars category is expected to hold a significant share of the global mammalian cell fermentation technology market in 2024. This segment is expected to expand as a result of factors such as rising demand for biologic medications, biologic medications' patent expirations, and government measures to encourage the use of biosimilars. The ability to produce vast quantities of high-quality biologic pharmaceuticals makes mammalian cell fermentation technology crucial for developing biosimilars. Mammalian cell fermentation technology is anticipated to be used more frequently to produce biosimilars as consumer demand for them rises. This is anticipated to fuel market expansion for mammalian cell fermentation technology, notably in the biosimilars sector.
CMOS & CDMOs Segment Witness Growth At A Rapid Rate
The CMOs & CDMOs segment is projected to grow at a rapid rate in the global mammalian cell fermentation technology market. CMOs and CDMOs are quickly evolving into the preferred choice for biotherapeutics producers because smaller businesses produce the majority of innovation in the bioprocess industry that lack the capacity, skilled personnel, and resources necessary for the commercialization of these products. The mammalian cell fermentation technology market's rise in this category is also anticipated to be aided by biologics' steadily expanding clinical pipeline.
The North America Mammalian Cell Fermentation Technology Market Holds Significant Revenue Share In The Region.
The North America mammalian cell fermentation technology market is expected to register the highest market share in revenue in the near future, attributed to the region's large number of contract development companies and the growing engagement of enterprises in biologics research and product development. The robust regulatory framework in North America significantly impacts the market for mammalian cell fermentation technology.
The biggest markets in the area are the United States, Canada, and Mexico. The rising demand for biologic medications, technical improvements, and governmental assistance for biotechnology research and development additionally fuels the market. In addition, Asia Pacific is projected to grow at a rapid rate in the global mammalian cell fermentation technology market. This expansion is fueled by various variables, including a sizable patient population, rising demand for biologic medications, government programs to assist biotechnology research and development, and increased contract manufacturing organizations (CMOs) in the area.
Mammalian Cell Fermentation Technology Market Report Scope:
|
Report Attribute |
Specifications |
|
Growth rate CAGR |
CAGR of 5% from 2024 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Billion, and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
|
Segments Covered |
Type, Application And End-Use |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; Southeast Asia |
|
Competitive Landscape |
Thermo Fisher Scientific, Inc.; Merck KGaA; Danaher; Lonza; Hoffmann-La Roche Ltd; Sartorius AG; AstraZeneca; Bristol-Myers Squibb; Amgen; Gilead Sciences; Moderna, Inc.; Regeneron Pharmaceuticals. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
